Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4894829 | 0.88 | AR (0.56) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL4595644 | 0.86 | TAS2R14 (0.52) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1363115 | 0.81 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1363920 | 0.81 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL12140104 | 0.81 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1291418 | 0.81 | TAS2R14 (0.51) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL13747842 | 0.80 | AR (0.48) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL15712966 | 0.80 | TAS2R14 (0.47) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1710048 | 0.79 | TAS2R14 (0.46) | ARPGRTAS2R14CYP2C19ABCB11 | |
| SCHEMBL1710017 | 0.79 | TAS2R14 (0.46) | ARPGRTAS2R14CYP2C19ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| EP-1871379-A2 | CYANOARYLAMINES | Smithkline Beecham Corporation (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006113552-A2 | CYANOARYLAMINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | EDNRA, CYP19A1, HSD17B11 | AR 84/4885PGR 64/4885TAS2R14 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.